stockrow
Saturday 7 November 2026
Export MLEC’s income statement to Excel — free account
Moolec Science SA
MLEC Healthcare Biotechnology
Moolec Science SA’s revenue for fiscal 2025 (year ended June 2025) was $333.6 million, up 5,830.7% from fiscal 2024.
- Revenue
- +948.4%
- EPS
- −20.0%
- Free cash flow
- +4.48%
Quarter to December 2025, against a year earlier
0.85
0.00
0.00%
Follow MLEC
Alert me
| Older periods | Jun '24 | Sep '24 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
7.51 | 6.25 | 3.98 | — | |
P/FCF ratio |
2.87 | 2.21 | 1.72 | — | |
P/Operating CF |
0.88 | (30.21) | (35.02) | — | |
P/B ratio |
0.17 | 5.97 | 11.15 | — | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | — | |
EV/Sales |
75.61 | 9.61 | 6.53 | — | |
EV/EBITDA |
11.43 | 1.40 | 1.37 | — | |
EV/Operating CF |
10.75 | 1.30 | 1.18 | — | |
EV/FCF |
28.92 | 3.40 | 2.82 | — | |
Quick Ratio |
0.73 | 0.71 | 0.72 | 0.08 | |
Current Ratio |
1.03 | 1.51 | 1.48 | 0.15 | |
Net Debt/EBITDA |
9.00 | (10.30) | (11.35) | 0.00 | |
Debt/Assets |
47.45% | 67.28% | 69.80% | 64.22% | |
Debt/Equity |
1.80 | 3.85 | 7.83 | 4.37 | |
Asset Turnover |
0.01 | 0.20 | 0.30 | 0.00 | |
Operating CF/Net income |
(18.87) | 0.59 | 0.37 | 0.00 | |
Capex/Depreciation |
(1.43) | (0.18) | (1.00) | (1.49) | |
Interest Coverage |
0.68 | (3.82) | (3.10) | — | |
Research and Development Expense of Revenue |
1,055.18% | 27.33% | 11.28% | — | |
Selling, General and Administrative Expense of Revenue |
7,926.10% | 113.64% | 41.93% | — | |
Intangible Assets out of Total Assets |
0.30 | 0.28 | 0.30 | 0.71 | |
Share Based Compensation of Revenue |
824.87% | 18.34% | (22.70%) | 0.00% | |
Graham Net Nets |
(6.20) | (0.46) | (0.61) | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(17.71%) | (23.50%) | (27.08%) | — | |
Free Cash Flow Yield |
34.83% | 45.18% | 58.17% | — | |
Revenue per Share |
6.01 | 6.03 | 10.17 | — | |
Operating CF per Share |
188.68 | (4.36) | (3.43) | 0.00 | |
Capex per Share |
(96.86) | (0.23) | (1.15) | 0.00 | |
Free Cash Flow per Share |
91.82 | (4.60) | (4.58) | 0.00 | |
Cash per Share |
266.83 | 13.99 | 7.43 | 0.00 | |
Shareholders Equity per Share |
985.90 | 22.07 | 10.76 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
985.90 | 22.07 | 10.76 | 0.00 | |
Free Cash Flow |
23.28 | (1.19) | (1.19) | (2.55) | |
Working Capital |
10.80 | 3.79 | 3.09 | (52.69) | |
Capital Expenditures |
(24.56) | (0.06) | (0.30) | (1.50) | |
Net Current Asset Value |
(261.63) | (15.71) | (19.04) | (79.01) | |
EV/EBIT |
22.05 | 2.69 | 2.67 | — | |
Capex to Sales |
16.13 | 0.04 | 0.11 | 0.00 | |
Price to Operating Income |
2.19 | 1.75 | 1.63 | — | |
| Other line items | |||||
Average Receivables |
123.01 | 1.72 | 1.97 | 2.94 | |
Average Payables |
88.21 | 5.22 | 3.79 | 5.17 | |
Average Inventory |
63.34 | 2.98 | 2.67 | 2.19 | |
Average Assets |
486.94 | 27.53 | 26.35 | 64.67 | |
Average Common Equity |
130.05 | 7.29 | 4.74 | 10.91 |
Columns are period end dates · fundamentals updated 26 Oct 2026